Evidence map›Paper›PMID 33856500›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2021

Development and validation of the risk engine for an Australian Health Economics Model of Osteoporosis.

L Si, J A Eisman, T Winzenberg, K M Sanders, J R Center, T V Nguyen, T Tran, A J Palmer

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Estimated health and economic effects associated with over- and under-exposure to solar ultraviolet radiation in Australia and New Zealand using the SUNEX simulation model.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

L SiThe George Institute for Global Health, UNSW Sydney, Kensington, Australia. lsi@georgeinstitute.org.au.ORCID http://orcid.org/0000-0002-3044-170X
J A EismanBone Biology Division, Garvan Institute of Medical Research, Sydney, Australia.
T WinzenbergMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
K M SandersDepartment of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia.
J R CenterBone Biology Division, Garvan Institute of Medical Research, Sydney, Australia.
T V NguyenBone Biology Division, Garvan Institute of Medical Research, Sydney, Australia.
T TranBone Biology Division, Garvan Institute of Medical Research, Sydney, Australia.
A J PalmerMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia. Andrew.Palmer@utas.edu.au.

Funding

National Health and Medical Research Council APP1127827National Health and Medical Research Council GNT1139826
6 · The paper itself

Abstract

The Australian Health Economics Model of Osteoporosis (AusHEMO) has shown good face, internal and cross validities, and can be used to assist healthcare decision-making in Australia. PURPOSE: This study aimed to document and validate the risk engine of the Australian Health Economics Model of Osteoporosis (AusHEMO).

methodsAusHEMO is a state-transition microsimulation model. The fracture risks were simulated using fracture incidence rates from the Dubbo Osteoporosis Epidemiology Study. The AusHEMO was validated regarding its face, internal and cross validities. Goodness-of-fit analysis was conducted and Lin's coefficient of agreement and mean absolute difference with 95% limits of agreement were reported.

resultsThe development of AusHEMO followed general and osteoporosis-specific health economics guidelines. AusHEMO showed good face validity regarding the model's structure, evidence, problem formulation and results. In addition, the model has been proven good internal and cross validities in goodness-of-fit test. Lin's coefficient was 0.99, 1 and 0.94 for validation against the fracture incidence rates, Australian life expectancies and residual lifetime fracture risks, respectively.

conclusionsIn summary, the development of the risk engine of AusHEMO followed the best practice for osteoporosis disease modelling and the model has been shown to have good face, internal and cross validities. The AusHEMO can be confidently used to predict long-term fracture-related outcomes and health economic evaluations when costs data are included. Health policy-makers in Australia can use the AusHEMO to select which osteoporosis interventions such as medications and public health interventions represent good value for money.

Indexed as

OsteoporosisOsteoporotic FracturesAustraliaCost-Benefit AnalysisHumansModels, EconomicAustralianEconomic evaluationHealth economics modelOsteoporosisOsteoporotic fracture

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.